Literature DB >> 17640227

Expression of activated Akt in benign nevi, Spitz nevi and melanomas.

Sara M Kantrow1, Alan S Boyd, Darrel L Ellis, Lillian B Nanney, Ann Richmond, Yu Shyr, Jason B Robbins.   

Abstract

BACKGROUND: Activated Akt expression (p-Akt) is reportedly increased in many melanomas as compared with benign nevi. The purpose of this study was to evaluate and compare p-Akt immunohistological staining in benign nevi, Spitz nevi and primary melanomas.
METHODS: Immunostaining for phosphorylated Akt was performed in 41 melanocytic lesions previously classified as benign intradermal nevus (14 lesions), Spitz nevus (9 lesions) or melanoma (18 lesions). Lesions were graded for intensity of p-Akt staining by two independent observers (0, no staining; 1, slightly positive; 2, moderately positive; 3, highly positive). Scores were averaged, and statistical analyses were performed.
RESULTS: Benign nevi showed less staining (mean score 1.18) compared with Spitz nevi (mean score 2.11) and melanomas (mean score 2.19). This difference was statistically significant between benign nevi and melanomas (p = 0.0047) and benign nevi and Spitz nevi (p = 0.0271). No statistical difference was detected in staining between Spitz nevi and melanomas (p = 0.8309).
CONCLUSIONS: Activated Akt expression is increased in Spitz nevi and melanomas as compared with benign intradermal nevi, but is unlikely to prove useful in differentiating between the former.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17640227      PMCID: PMC2665272          DOI: 10.1111/j.1600-0560.2006.00675.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  30 in total

Review 1.  NF-kappaB at the crossroads of life and death.

Authors:  Michael Karin; Anning Lin
Journal:  Nat Immunol       Date:  2002-03       Impact factor: 25.606

2.  A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas.

Authors:  R Bergman; H Azzam; E Sprecher; L Manov; M Munichor; R Friedman-Birnbaum; O Ben-Itzhak
Journal:  J Am Acad Dermatol       Date:  2000-03       Impact factor: 11.527

3.  Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma.

Authors:  S P Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

4.  Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.

Authors:  Y Isabel Zhu; James E Fitzpatrick
Journal:  J Cutan Pathol       Date:  2006-01       Impact factor: 1.587

5.  The Spitzoid lesion: rethinking Spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment.

Authors:  Raymond L Barnhill
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

6.  Typical, dysplastic, congenital, and Spitz nevi: a comparative immunohistochemical study.

Authors:  J Palazzo; P H Duray
Journal:  Hum Pathol       Date:  1989-04       Impact factor: 3.466

7.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.

Authors:  J Q Cheng; A K Godwin; A Bellacosa; T Taguchi; T F Franke; T C Hamilton; P N Tsichlis; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

8.  Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression.

Authors:  Punita Dhawan; Amar B Singh; Darrel L Ellis; Ann Richmond
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

9.  Deregulated Akt3 activity promotes development of malignant melanoma.

Authors:  Jill M Stahl; Arati Sharma; Mitchell Cheung; Melissa Zimmerman; Jin Q Cheng; Marcus W Bosenberg; Mark Kester; Lakshman Sandirasegarane; Gavin P Robertson
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

Review 10.  PI3K/Akt signalling pathway and cancer.

Authors:  Juan Angel Fresno Vara; Enrique Casado; Javier de Castro; Paloma Cejas; Cristóbal Belda-Iniesta; Manuel González-Barón
Journal:  Cancer Treat Rev       Date:  2004-04       Impact factor: 12.111

View more
  8 in total

1.  mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.

Authors:  William Damsky; Goran Micevic; Katrina Meeth; Viswanathan Muthusamy; David P Curley; Manjula Santhanakrishnan; Ildiko Erdelyi; James T Platt; Laura Huang; Nicholas Theodosakis; M Raza Zaidi; Scott Tighe; Michael A Davies; David Dankort; Martin McMahon; Glenn Merlino; Nabeel Bardeesy; Marcus Bosenberg
Journal:  Cancer Cell       Date:  2015-01-12       Impact factor: 31.743

2.  Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.

Authors:  William D Tap; Ke-Wei Gong; Judy Dering; Yiou Tseng; Charles Ginther; Giovanni Pauletti; John A Glaspy; Richard Essner; Gideon Bollag; Peter Hirth; Chao Zhang; Dennis J Slamon
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

Review 3.  Melanocytic nevi and melanoma: unraveling a complex relationship.

Authors:  W E Damsky; M Bosenberg
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

4.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Authors:  Mitchell Cheung; Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 5.  Immune-phenotypical markers for the differential diagnosis of melanocytic lesions.

Authors:  Gerardo Botti; Laura Marra; Annamaria Anniciello; Giosuè Scognamiglio; Vincenzo Gigantino; Monica Cantile
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 6.  Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.

Authors:  Lawrence N Kwong; Michael A Davies
Journal:  Clin Cancer Res       Date:  2013-10-01       Impact factor: 12.531

Review 7.  Understanding signaling cascades in melanoma.

Authors:  Pablo Lopez-Bergami; Boris Fitchman; Ze'ev Ronai
Journal:  Photochem Photobiol       Date:  2007-12-15       Impact factor: 3.421

8.  MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab.

Authors:  Aubrey G Wagenseller; Amber Shada; Kevin M D'Auria; Cheryl Murphy; Dandan Sun; Kerrington R Molhoek; Jason A Papin; Anindya Dutta; Craig L Slingluff
Journal:  J Transl Med       Date:  2013-09-18       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.